Plus   Neg

AstraZeneca : Lynparza Reduces Risk Of Disease Progression In HRR Gene Mutations

AstraZeneca (AZN.L,AZN) and Merck & Co., Inc. said that Lynparza more than doubled the time without radiographic disease progression in patients with BRCA1/2- or ATM-mutated metastatic castration-resistant prostate cancer.

AstraZeneca and Merck's Lynparza reduced the risk of disease progression or death by 51% in men with homologous recombination repair or HRR gene mutations.

It was the first positive Phase III trial testing a targeted treatment in biomarker-selected prostate cancer patients, the companies said.

The companies presented detailed results from the Phase III PROfound trial in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who have a mutation in their homologous recombination repair (HRRm) genes and whose disease had progressed on prior treatment with new hormonal agent (NHA) treatments.

For comments and feedback contact: editorial@rttnews.com

Follow RTT